查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1977600

2026-2034年全球抗凝血酶市场规模、份额、趋势和成长分析报告

Global Antithrombin Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 140 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计抗凝血酶市场将从 2025 年的 9.3 亿美元成长到 2034 年的 14.4 亿美元，2026 年至 2034 年的复合年增长率为 4.94%。

由于血栓性疾病和血液凝固併发症的发生率不断上升，全球抗凝血酶市场正稳步扩张。抗凝血酶在预防异常血栓形成方面发挥着至关重要的作用，尤其是在手术和高风险怀孕期间。人们对心血管健康的日益关注也促进了治疗方法的应用。医疗基础设施的扩建进一步推动了市场成长。

成长要素包括血浆衍生抗凝血酶和重组抗凝血酶疗法的进步。遗传性凝血障碍盛行率的上升推动了对标靶治疗的需求。外科手术量和加加护病房入院人数的增加也是重要的推动因素。此外，诊断筛检的改善提高了早期疗育率。

随着新型抗凝血疗法的研发不断推进，未来前景乐观。更安全、更有效的製剂的研发将扩大病患的用药范围。新兴市场对先进医疗服务的投资也带来了新的成长机会。预计抗凝血酶市场将稳定持续成长。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

  • 市场谱系展望
  • 渗透率和成长前景分析
  • 价值链分析
  • 法律规范
    • 标准与合规性
    • 监管影响分析
  • 市场动态
    • 市场驱动因素
    • 市场限制因素
    • 市场机会
    • 市场挑战
  • 波特五力分析
  • PESTLE分析

第四章：全球抗凝血酶市场：依技术与应用划分

  • 市场分析、洞察与预测
  • 治疗
  • 调查
  • 诊断

第五章：全球抗凝血酶市场：依来源划分

  • 市场分析、洞察与预测
  • 人类
  • 羊奶
  • 其他的

第六章：全球抗凝血酶市场：依剂型划分

  • 市场分析、洞察与预测
  • 冷冻干燥製剂
  • 液体

第七章 全球抗凝血酶市场：依地区划分

  • 区域分析
  • 北美市场分析、洞察与预测
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲市场分析、洞察与预测
    • 英国
    • 法国
    • 德国
    • 义大利
    • 俄罗斯
    • 其他欧洲国家
  • 亚太市场分析、洞察与预测
    • 印度
    • 日本
    • 韩国
    • 澳洲
    • 东南亚
    • 亚太其他地区
  • 拉丁美洲市场分析、洞察与预测
    • 巴西
    • 阿根廷
    • 秘鲁
    • 智利
    • 其他拉丁美洲国家
  • 中东和非洲市场分析、洞察与预测
    • 沙乌地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中东和非洲国家

第八章 竞争情势

  • 最新趋势
  • 公司分类
  • 供应链和销售管道合作伙伴（根据现有资讯）
  • 市场占有率和市场定位分析（基于现有资讯）
  • 供应商情况（基于现有资讯）
  • 策略规划

第九章：公司简介

  • 主要公司的市占率分析
  • 公司简介
    • Grifols SA
    • Octapharma AG
    • LFB USA
    • CSL
    • Takeda Pharmaceutical Company Limited
    • Lee BioSolutions
    • Scrippslabs
    • Kedrion
    • Koliber Biosciences
    • Exonbio
    • Helena Laboratories Corporation
    • MyBioSource.Com
简介目录
Product Code: VMR11211454

The Antithrombin Market size is expected to reach USD 1.44 Billion in 2034 from USD 0.93 Billion (2025) growing at a CAGR of 4.94% during 2026-2034.

The Global Antithrombin market has expanded steadily due to increasing incidence of thrombotic disorders and blood clotting complications. Antithrombin plays a critical role in preventing abnormal clot formation, especially during surgeries and high-risk pregnancies. Rising awareness about cardiovascular health has contributed to growing treatment adoption. Expanding healthcare infrastructure further supports market development.

Growth drivers include advancements in plasma-derived and recombinant antithrombin therapies. Increased prevalence of genetic clotting disorders boosts demand for targeted treatments. Growing surgical procedures and intensive care admissions also contribute significantly. Additionally, improvements in diagnostic screening enhance early intervention rates.

Future prospects appear favorable as research into novel anticoagulant therapies progresses. Development of safer and more effective formulations will expand patient access. Emerging markets investing in advanced healthcare services present new growth opportunities. The antithrombin market is expected to witness stable and sustained expansion.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Technology Application

  • Therapeutics
  • Research
  • Diagnostics

By Source

  • Human
  • Goat Milk
  • Others

By Dosage Form

  • Lyophilized
  • Liquid

COMPANIES PROFILED

  • Grifols SA, Octapharma AG, LFB USA, CSL, Takeda Pharmaceutical Company Limited, Lee BioSolutions, scrippslabs, Kedrion, Koliber Biosciences, exonbio, Helena Laboratories Corporation, MyBioSourcecom
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL ANTITHROMBIN MARKET: BY TECHNOLOGY APPLICATION 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Technology Application
  • 4.2. Therapeutics Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Research Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Diagnostics Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ANTITHROMBIN MARKET: BY SOURCE 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Source
  • 5.2. Human Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Goat Milk Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ANTITHROMBIN MARKET: BY DOSAGE FORM 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Dosage Form
  • 6.2. Lyophilized Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Liquid Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ANTITHROMBIN MARKET: BY REGION 2022-2034(USD MN)

  • 7.1. Regional Outlook
  • 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.2.1 By Technology Application
    • 7.2.2 By Source
    • 7.2.3 By Dosage Form
    • 7.2.4 United States
    • 7.2.5 Canada
    • 7.2.6 Mexico
  • 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.3.1 By Technology Application
    • 7.3.2 By Source
    • 7.3.3 By Dosage Form
    • 7.3.4 United Kingdom
    • 7.3.5 France
    • 7.3.6 Germany
    • 7.3.7 Italy
    • 7.3.8 Russia
    • 7.3.9 Rest Of Europe
  • 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.4.1 By Technology Application
    • 7.4.2 By Source
    • 7.4.3 By Dosage Form
    • 7.4.4 India
    • 7.4.5 Japan
    • 7.4.6 South Korea
    • 7.4.7 Australia
    • 7.4.8 South East Asia
    • 7.4.9 Rest Of Asia Pacific
  • 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.5.1 By Technology Application
    • 7.5.2 By Source
    • 7.5.3 By Dosage Form
    • 7.5.4 Brazil
    • 7.5.5 Argentina
    • 7.5.6 Peru
    • 7.5.7 Chile
    • 7.5.8 South East Asia
    • 7.5.9 Rest of Latin America
  • 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.6.1 By Technology Application
    • 7.6.2 By Source
    • 7.6.3 By Dosage Form
    • 7.6.4 Saudi Arabia
    • 7.6.5 UAE
    • 7.6.6 Israel
    • 7.6.7 South Africa
    • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

  • 8.1. Recent Developments
  • 8.2. Company Categorization
  • 8.3. Supply Chain & Channel Partners (based on availability)
  • 8.4. Market Share & Positioning Analysis (based on availability)
  • 8.5. Vendor Landscape (based on availability)
  • 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL ANTITHROMBIN INDUSTRY

  • 9.1. Top Companies Market Share Analysis
  • 9.2. Company Profiles
    • 9.2.1 Grifols S.A
    • 9.2.2 Octapharma AG
    • 9.2.3 LFB USA
    • 9.2.4 CSL
    • 9.2.5 Takeda Pharmaceutical Company Limited
    • 9.2.6 Lee BioSolutions
    • 9.2.7 Scrippslabs
    • 9.2.8 Kedrion
    • 9.2.9 Koliber Biosciences
    • 9.2.10 Exonbio
    • 9.2.11 Helena Laboratories Corporation
    • 9.2.12 MyBioSource.Com